The Latest in Multiple Sclerosis Hub

Relapsing, progressive MS classifications should be abandoned

June 16, 2020

Multiple Sclerosis

FDA approves Uplizna for treatment of anti-AQP4 antibody–positive NMOSD

June 15, 2020

Multiple Sclerosis

Cannabis misconceptions still common among MS clinicians

June 8, 2020

Multiple Sclerosis

Function in MS may vary significantly within EDSS scores

June 8, 2020

Multiple Sclerosis

Herpes zoster infection with MS treatment higher in women?

June 5, 2020

Multiple Sclerosis

Newest oral DMTs haven’t yet made a big impact in the MS world

June 4, 2020

Multiple Sclerosis

Constraint-induced movement therapy may boost neuroplasticity in MS

June 3, 2020

Multiple Sclerosis

Telerehabilitation may be effective in MS

June 1, 2020

Multiple Sclerosis

No benefit of three commonly used medications for MS fatigue

June 1, 2020

Multiple Sclerosis

Ofatumumab shows high elimination of disease activity in MS

May 29, 2020

Multiple Sclerosis

Natalizumab switch to moderate-efficacy DMT increases disability risk

May 28, 2020

Multiple Sclerosis

High levels of air pollution linked to increased MS risk

May 28, 2020

Multiple Sclerosis

Natalizumab bests fingolimod for relapsing-remitting MS

May 14, 2020

Multiple Sclerosis

Serum NfL in early MS can help predict clinical course

May 7, 2020

Multiple Sclerosis

Initial high-efficacy MS therapy tied to less disability later

May 5, 2020

Multiple Sclerosis